229 related articles for article (PubMed ID: 26900152)
41. Biochemical and structural study of the atypical acyltransferase domain from the mycobacterial polyketide synthase Pks13.
Bergeret F; Gavalda S; Chalut C; Malaga W; Quémard A; Pedelacq JD; Daffé M; Guilhot C; Mourey L; Bon C
J Biol Chem; 2012 Sep; 287(40):33675-90. PubMed ID: 22825853
[TBL] [Abstract][Full Text] [Related]
42. AcpM, the meromycolate extension acyl carrier protein of Mycobacterium tuberculosis, is activated by the 4'-phosphopantetheinyl transferase PptT, a potential target of the multistep mycolic acid biosynthesis.
Zimhony O; Schwarz A; Raitses-Gurevich M; Peleg Y; Dym O; Albeck S; Burstein Y; Shakked Z
Biochemistry; 2015 Apr; 54(14):2360-71. PubMed ID: 25785780
[TBL] [Abstract][Full Text] [Related]
43. Reassessing the putative molecular Target(s) of potent antitubercular 2-(Alkylsulfonyl)acetamides.
Farr DC; Haselhorst T; Tan L; Furness J; Strong E; Grice ID; West NP; Houston TA
Eur J Med Chem; 2024 Jan; 264():115983. PubMed ID: 38048695
[TBL] [Abstract][Full Text] [Related]
44. Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors.
Fang C; Lee KK; Nietupski R; Bates RH; Fernandez-Menendez R; Lopez-Roman EM; Guijarro-Lopez L; Yin Y; Peng Z; Gomez JE; Fisher S; Barros-Aguirre D; Hubbard BK; Serrano-Wu MH; Hung DT
Bioorg Med Chem Lett; 2018 Dec; 28(22):3529-3533. PubMed ID: 30316633
[TBL] [Abstract][Full Text] [Related]
45. Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis.
Kremer L; Douglas JD; Baulard AR; Morehouse C; Guy MR; Alland D; Dover LG; Lakey JH; Jacobs WR; Brennan PJ; Minnikin DE; Besra GS
J Biol Chem; 2000 Jun; 275(22):16857-64. PubMed ID: 10747933
[TBL] [Abstract][Full Text] [Related]
46. The Mycobacterium tuberculosis FAS-II condensing enzymes: their role in mycolic acid biosynthesis, acid-fastness, pathogenesis and in future drug development.
Bhatt A; Molle V; Besra GS; Jacobs WR; Kremer L
Mol Microbiol; 2007 Jun; 64(6):1442-54. PubMed ID: 17555433
[TBL] [Abstract][Full Text] [Related]
47. Targeting the mycobacterial envelope for tuberculosis drug development.
Favrot L; Ronning DR
Expert Rev Anti Infect Ther; 2012 Sep; 10(9):1023-36. PubMed ID: 23106277
[TBL] [Abstract][Full Text] [Related]
48. [Characterization of fatty acids and mycolic acid degradation products in mycobacterial species of major incidence in Argentina].
Zerbini E; Cardoso M; Sequeira M; Taher H; Santi N; Larpin D; Latini O; Tonarelli G
Rev Argent Microbiol; 1997; 29(4):184-94. PubMed ID: 9472140
[TBL] [Abstract][Full Text] [Related]
49. Inhibitors of an essential mycobacterial cell wall lipase (Rv3802c) as tuberculosis drug leads.
West NP; Cergol KM; Xue M; Randall EJ; Britton WJ; Payne RJ
Chem Commun (Camb); 2011 May; 47(18):5166-8. PubMed ID: 21384024
[TBL] [Abstract][Full Text] [Related]
50. Structural basis for the recognition of mycolic acid precursors by KasA, a condensing enzyme and drug target from Mycobacterium tuberculosis.
Schiebel J; Kapilashrami K; Fekete A; Bommineni GR; Schaefer CM; Mueller MJ; Tonge PJ; Kisker C
J Biol Chem; 2013 Nov; 288(47):34190-34204. PubMed ID: 24108128
[TBL] [Abstract][Full Text] [Related]
51. Bisubstrate adenylation inhibitors of biotin protein ligase from Mycobacterium tuberculosis.
Duckworth BP; Geders TW; Tiwari D; Boshoff HI; Sibbald PA; Barry CE; Schnappinger D; Finzel BC; Aldrich CC
Chem Biol; 2011 Nov; 18(11):1432-41. PubMed ID: 22118677
[TBL] [Abstract][Full Text] [Related]
52. In Silico Drug Repurposing Approach: Investigation of
Ngidi NTP; Machaba KE; Mhlongo NN
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163931
[No Abstract] [Full Text] [Related]
53.
Nunes JES; Duque MA; de Freitas TF; Galina L; Timmers LFSM; Bizarro CV; Machado P; Basso LA; Ducati RG
Molecules; 2020 Mar; 25(6):. PubMed ID: 32168746
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of the inhibitory activity of (aza)isoindolinone-type compounds: toward in vitro InhA action, Mycobacterium tuberculosis growth and mycolic acid biosynthesis.
Chollet A; Stigliani JL; Pasca MR; Mori G; Lherbet C; Constant P; Quémard A; Bernadou J; Pratviel G; Bernardes-Génisson V
Chem Biol Drug Des; 2016 Nov; 88(5):740-755. PubMed ID: 27301022
[TBL] [Abstract][Full Text] [Related]
55. Structural basis for the development of potential inhibitors targeting FadD23 from Mycobacterium tuberculosis.
Yan M; Ma M; Chen R; Cao Y; Zhang W; Liu X
Acta Crystallogr F Struct Biol Commun; 2023 Aug; 79(Pt 8):208-216. PubMed ID: 37522751
[TBL] [Abstract][Full Text] [Related]
56. Structural and functional studies of mycobacterial IspD enzymes.
Björkelid C; Bergfors T; Henriksson LM; Stern AL; Unge T; Mowbray SL; Jones TA
Acta Crystallogr D Biol Crystallogr; 2011 May; 67(Pt 5):403-14. PubMed ID: 21543842
[TBL] [Abstract][Full Text] [Related]
57. MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-II.
Marrakchi H; Ducasse S; Labesse G; Montrozier H; Margeat E; Emorine L; Charpentier X; Daffé M; Quémard AK
Microbiology (Reading); 2002 Apr; 148(Pt 4):951-960. PubMed ID: 11932442
[TBL] [Abstract][Full Text] [Related]
58. Rv0132c of Mycobacterium tuberculosis encodes a coenzyme F420-dependent hydroxymycolic acid dehydrogenase.
Purwantini E; Mukhopadhyay B
PLoS One; 2013; 8(12):e81985. PubMed ID: 24349169
[TBL] [Abstract][Full Text] [Related]
59. Adenylating enzymes in Mycobacterium tuberculosis as drug targets.
Duckworth BP; Nelson KM; Aldrich CC
Curr Top Med Chem; 2012; 12(7):766-96. PubMed ID: 22283817
[TBL] [Abstract][Full Text] [Related]
60. 4'-Phosphopantetheinyl transferase PptT, a new drug target required for Mycobacterium tuberculosis growth and persistence in vivo.
Leblanc C; Prudhomme T; Tabouret G; Ray A; Burbaud S; Cabantous S; Mourey L; Guilhot C; Chalut C
PLoS Pathog; 2012 Dec; 8(12):e1003097. PubMed ID: 23308068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
